Effect of prophylactic human papillomavirus L1 virus-like-particle vaccine on risk of cervical intraepithelial neoplasia grade 2, grade 3, and adenocarcinoma in situ: a combined analysis of four randomised clinical trials
Cited by 586
Abstract
Related Papers
Quadrivalent Vaccine against Human Papillomavirus to Prevent High-Grade Cervical Lesions
The FUTURE II Study Group|New England Journal of Medicine|2007|2.1k
Quadrivalent Vaccine against Human Papillomavirus to Prevent Anogenital Diseases
Suzanne M. Garland, Mauricio Hernández‐Ávila, Cosette M. Wheeler et al.|New England Journal of Medicine|2007|1.9k
Prophylactic quadrivalent human papillomavirus (types 6, 11, 16, and 18) L1 virus-like particle vaccine in young women: a randomised double-blind placebo-controlled multicentre phase II efficacy trial
Luisa L. Villa, Ronaldo Lúcio Rangel Costa, Carlos Alberto Petta et al.|The Lancet Oncology|2005|1.6k